Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nanobiotix S.A. ADR (NBTX)

Nanobiotix S.A. ADR (NBTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 157,896
  • Shares Outstanding, K 47,133
  • Annual Sales, $ 39,190 K
  • Annual Income, $ -42,970 K
  • EBIT $ 0 M
  • EBITDA $ -27 M
  • 60-Month Beta 0.33
  • Price/Sales 4.17
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.25 +3.08%
on 11/27/24
4.70 -28.80%
on 10/29/24
-1.24 (-27.02%)
since 10/25/24
3-Month
3.25 +3.08%
on 11/27/24
6.00 -44.17%
on 08/30/24
-1.78 (-34.70%)
since 08/27/24
52-Week
3.25 +3.08%
on 11/27/24
8.96 -62.62%
on 01/18/24
-2.19 (-39.56%)
since 11/27/23

Most Recent Stories

More News
Nanobiotix: Voting Rights and Shares Capital of the Company

Regulatory News:

NANO : 35.33 (-0.81%)
NBTX : 3.35 (-3.46%)
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022

Regulatory News:

NBTX : 3.35 (-3.46%)
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022

Regulatory News:

NBTX : 3.35 (-3.46%)
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Regulatory News:

NBTX : 3.35 (-3.46%)
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024

Regulatory News:

NBTX : 3.35 (-3.46%)
Nanobiotix: Voting Rights and Shares Capital of the Company

Regulatory News:

NANO : 35.33 (-0.81%)
NBTX : 3.35 (-3.46%)
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

Regulatory News:

NBTX : 3.35 (-3.46%)
LIAN : 0.3190 (-8.28%)
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences

Regulatory News:

NANO : 35.33 (-0.81%)
NBTX : 3.35 (-3.46%)
Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022

Regulatory News:

NANO : 35.33 (-0.81%)
NBTX : 3.35 (-3.46%)
NANOBIOTIX: Voting Rights and Shares Capital of the Company

Regulatory News:

NANO : 35.33 (-0.81%)
NBTX : 3.35 (-3.46%)

Business Summary

Nanobiotix S.A. is a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer. The company's proprietary technology includes NBTXR3. Nanobiotix S.A. is headquartered in Paris, France.

See More

Key Turning Points

3rd Resistance Point 3.64
2nd Resistance Point 3.54
1st Resistance Point 3.45
Last Price 3.35
1st Support Level 3.25
2nd Support Level 3.15
3rd Support Level 3.06

See More

52-Week High 8.96
Fibonacci 61.8% 6.78
Fibonacci 50% 6.11
Fibonacci 38.2% 5.43
Last Price 3.35
52-Week Low 3.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar